• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Gilead Sciences (NQ:GILD)

    130.68 -0.47 (-0.36%)
    Streaming Delayed Price Updated: 11:49 AM EDT, Aug 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Gilead Sciences

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    21 22 Next >
    News headline image
    CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
    From Gilead Sciences, Inc.
    Via Business Wire
    MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition
    Via Investor Brand Network
    News headline image
    U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
    From Gilead Sciences, Inc.
    Via Business Wire
    Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
    Via Investor Brand Network
    BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
    From BioMedWire
    Via GlobeNewswire
    News headline image
    U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Prices $3 Billion of Senior Unsecured Notes
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Sciences Announces First Quarter Financial Results
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
    From Gilead Sciences, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    21 22 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.